DIKACINE DIKACINE DIKACINE

Dose: 50 mg
Single Dose: 50 (50)
Frequency: 12 hourly
Route: IM,IV Inf
Instructions:

Dose: 3 to 4 mg/kg
Single Dose: 3.5 (3.5)
Frequency: 24 hourly
Route: Intramuscular
Instructions:

Dose: 1 to 2 mg/kg
Single Dose: 1.5 (1.5)
Frequency: 24 hourly
Route: Intramuscular
Instructions:

. It is of Semi Synthetic origin and belongs to Aminoglycoside. It belongs to Antibacterial (Proetin synthesis inhibitor) pharmacological group on the basis of mechanism of action. The Molecular Weight of Dibekacin is 451.50.

Dibekacin is contraindicated in conditions like Hypersensitivity to the drug.

Dibekacin produces potentially life-threatening effects which include Nephrotoxicity, Acute Renal Failure, Acute renal failure, Ototoxicity. which are responsible for the discontinuation of Dibekacin therapy.The symptomatic adverse reactions produced by Dibekacin are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Vertigo, Hypersensitivity, Hearing loss, Respiratory depression, Azotemia, dizziness, Decreased Glomerular, Muscular paralysis.

Dibekacin is primarily indicated in conditions like Endocarditis, Prostatitis, Respiratory tract infections, Skin infections, Soft tissue infections, Surgical infections, Urinary tract infection.

No data regarding the interactions of Dibekacin was found.

Drug should not be given to Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Use with caution in patients with impaired renal function, impaired hepatic function and in aged patients, in case of ypersensitivity to any aminoglycoside antibiotic and in patient suffering from hearing loss due to administration of any ototoxic drug.